Serplulimab
| Clinical data | |
|---|---|
| Other names | HLX10 |
| Routes of administration | Intravenous |
| Drug class | Antineoplastic agent |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Serplulimab is a monoclonal antibody used for the treatment of cancers.[1][2]
Society and culture
[edit]Legal status
[edit]It was approved for medical use in China in 2022, for the treatment of microsatellite instability-high solid tumors,[2] and in 2023 for the treatment of esophageal squamous cell carcinoma.[3]
In September 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Hetronifly, intended for the treatment of extensive-stage small cell lung cancer (ES-SCLC).[1] The applicant for this medicinal product is Henlius Europe GmbH.[1]
Names
[edit]Serplulimab is the International nonproprietary name.[4]
References
[edit]- ^ a b c "Hetronifly EPAR". European Medicines Agency (EMA). 19 September 2024. Retrieved 21 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b Lee A (July 2022). "Serplulimab: First Approval". Drugs. 82 (10): 1137–1141. doi:10.1007/s40265-022-01740-0. PMID 35796953.
- ^ "Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ESCC-Media". Henlius (Press release). 22 September 2023. Retrieved 21 September 2024.
- ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
Further reading
[edit]- Qin S, Li J, Zhong H, Jin C, Chen L, Yuan X, et al. (December 2022). "Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial". British Journal of Cancer. 127 (12): 2241–2248. doi:10.1038/s41416-022-02001-3. PMC 9726893. PMID 36261583.
- Wang ZX, Peng J, Liang X, Cheng Y, Deng Y, Chen K, et al. (September 2024). "First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial". Med (New York, N.Y.). 5 (9): 1150–1163.e3. doi:10.1016/j.medj.2024.05.009. PMID 38870931.
- Xiang G, Jiang T, Gan L, Wu Y, Zhang N, Xing H, et al. (2023). "Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China". Frontiers in Immunology. 14: 1223020. doi:10.3389/fimmu.2023.1223020. PMC 10501445. PMID 37720211.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |